Oncology

Pharma News and Updates for AbbVie, Arrowhead Pharma, Novartis, FORE Biotherapeutics, Ellipses Pharma, Karuna Therapeutics

Notizia - Recent Pharma, Healthcare and Biotech Happenings

AbbVie Announces Results of Study Evaluating SKYRIZI; FDA Fast Track Designation to Arrowhead’s ARO-APOC3; FDA Approves Dabrafenib Plus Trametinib for BRAF V600E–Mutated Low-Grade Glioma; FDA Grants ODD to Novel BRAF Inhibitor for Brain/CNS Malignancies; EP0042 Wins FDA Orphan Drug Status; Karuna Therapeutics Announces Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

AbbVie Announces Positive Results of Study Evaluating SKYRIZI in Plaque Psoriasis Patients AbbVie announced new 52-week data from an open-label, a single-arm study demonstrating improved plaque psoriasis signs and symptoms in a difficult-to-treat patient population who received SKYRIZI® (risankizumab), an IL-23 inhibitor. These patients had a suboptimal response to secukinumab or ixekizumab, both IL-17A inhibitor therapies, for at least six months before switching to risankizumab. The findings were presented at a Late-Breaking Research session at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans, Louisiana. "The evidence presented at ...

Explore More...

skin-cancer-treatment-market-and-key-companies

Key Pharma Companies Expanding their Arm in the Skin Cancer Segment

Latest-pharma-happenings-for-rallybio-sanofi-eureka-lilly-unity-biotechnology

Unity’s advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka’s candidate; Lilly invests in MiNA;

pharma-happenings-for-arrowhead-sartorius-sirnaomics-agc-biologics

Arrowhead’s ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics’s Cell & Gene Therapy; Sirnaomics Secures $105 Million

Horizon-Arrowhead-deal-Dr-Reddy-Lab-Drug-US-Launch-Targovax-ONCOS-102;-RedHill-Oral-Opaganib-COVID-19

Amgen a leader in Undruggable Lung Cancer; Verrica’s Skin Disease Drug Delays; Fennec’s Faith in its Chemotherapy-Induced Hearing Loss Drug; Nexturn Bio’s Acquisition of RosVivo

Another Failed NASH Drug; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; TLX66 in AL Amyloidosis

TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug

recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos

InnoCare’s Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab

recent-pharma-happenings-for-eli-lilly-mina-appia-bio-nuvalent

Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids

recent-pharma-biotech-news-updates-happenings-for-abbott-biogen-eli-lilly-arch-oncology

Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med

recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa

Adagio Raises $336 M; Lyndra’s Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy

Ewing Sarcoma: Key Companies and Emerging Therapies in the Landscape

recent-pharma-happenings-for-recursion-repertoire-cequr-eli-lilly

Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO

recent-pharma-news-and-updates-for-astrazeneca-sanofi-taysha

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Oncology

Key Pharma Companies Expanding their Arm in the Skin Cancer Segment

Unity’s advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka’s candidate; Lilly invests in MiNA;

Arrowhead’s ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics’s Cell & Gene Therapy; Sirnaomics Secures $105 Million

Horizon/ Arrowhead Deal; Dr Reddy’s Lab’s Drug US Launch; Targovax’s ONCOS-102; RedHill’s Oral Opaganib in COVID-19

Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M

Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M

Diagnosis Delays, Ineffective Treatment Options Plaque the Bone Cancer Market Growth

Amgen a leader in Undruggable Lung Cancer; Verrica’s Skin Disease Drug Delays; Fennec’s Faith in its Chemotherapy-Induced Hearing Loss Drug; Nexturn Bio’s Acquisition of RosVivo

More Views & Analysis

TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug

InnoCare’s Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab

Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids

Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med

Adagio Raises $336 M; Lyndra’s Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy

Ewing Sarcoma: Key Companies and Emerging Therapies in the Landscape

Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO

Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities

Subscribe to our Updates

Daily

Weekly

Monthly